Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Corneal Neovascularization D016510 8 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Helicobacter Infections D016481 21 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Milk Hypersensitivity D016269 4 associated lipids
Blood Loss, Surgical D016063 6 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
HIV Infections D015658 20 associated lipids
AIDS Dementia Complex D015526 4 associated lipids
Leukemia, Eosinophilic, Acute D015472 3 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Reperfusion Injury D015427 65 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Xeroderma Pigmentosum D014983 6 associated lipids
Wounds and Injuries D014947 20 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Viremia D014766 4 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Uremia D014511 33 associated lipids
Tumor Virus Infections D014412 8 associated lipids
Toxemia D014115 3 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Thrombosis D013927 49 associated lipids
Thrombocytosis D013922 4 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombasthenia D013915 4 associated lipids
Thalassemia D013789 8 associated lipids
Tangier Disease D013631 8 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Subacute Sclerosing Panencephalitis D013344 3 associated lipids
Stomatitis D013280 14 associated lipids
Stomach Ulcer D013276 75 associated lipids
Staphylococcal Skin Infections D013207 9 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Spasm D013035 5 associated lipids
Sneezing D012912 6 associated lipids
Shock, Traumatic D012774 4 associated lipids
Shock, Septic D012772 11 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Ou MC et al. Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. 1994 Thromb. Res. pmid:8191415
Bochkov VN et al. LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II. 1991 Thromb. Res. pmid:2063348
Bush LR and Smith SG Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. 1986 Thromb. Res. pmid:2948294
Filep JG et al. C-reactive protein inhibits binding of platelet-activating factor to human platelets. 1991 Thromb. Res. pmid:2063349
Slattery CW and Beaumont DO Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. 1989 Thromb. Res. pmid:2554526
Belch JJ et al. Whole blood white cell aggregation: a novel technique. 1987 Thromb. Res. pmid:2448894
Nguyên P et al. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. 1995 Thromb. Res. pmid:7778064
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Sturk A et al. Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. 1985 Thromb. Res. pmid:2934863
Namm DH et al. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. 1982 Thromb. Res. pmid:7071810
Westwick J et al. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. 1986 Thromb. Res. pmid:3715810
Brown JE and Thuy LP The binding of bovine platelet aggregating factor to human platelets. 1981 Apr 1-15 Thromb. Res. pmid:7292446
Ishii H et al. Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. 1990 Thromb. Res. pmid:2382255
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. 1987 Thromb. Res. pmid:3647677
Hofmann B et al. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. 1988 Thromb. Res. pmid:3381200
Davis RB and Johnson MF Effects of bacterial endotoxin and platelet activating factor (PAF) on human platelet aggregation in native whole blood. 1986 Thromb. Res. pmid:3544327
Glusa E et al. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. 1989 Thromb. Res. pmid:2528843
Stahl GL et al. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. 1989 Thromb. Res. pmid:2718150
Sloan IG and Firkin BG Impaired fibrinolysis in patients with thrombotic or haemostatic defects. 1989 Thromb. Res. pmid:2814943
Skeaff CM and Holub BJ The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. 1988 Thromb. Res. pmid:3187952
Griffin KJ and Levy JV The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF). 1988 Thromb. Res. pmid:3187959
Ostermann G et al. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. 1984 Thromb. Res. pmid:6710440
Beaumont DO et al. Measuring platelet function with platelet shape change, an early event in aggregation. 1989 Thromb. Res. pmid:2646752
Janero DR et al. Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. 1988 Thromb. Res. pmid:3413730
Moon DG et al. Platelet activating factor and sheep platelets: a sensitive new bioassay. 1990 Thromb. Res. pmid:2326773
Benveniste J et al. Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. 1982 Thromb. Res. pmid:6803388
Seth P et al. Effect of platelet activating factor antagonists in different models of thrombosis. 1994 Thromb. Res. pmid:7900097
Klöcking HP et al. Release of tissue-type plasminogen activator by platelet-activating factor. 1985 Thromb. Res. pmid:4040278
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Vrzheshch PV et al. Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. 1992 Thromb. Res. pmid:1523610
Teng CM et al. Antiplatelet actions of some coumarin compounds isolated from plant sources. 1992 Thromb. Res. pmid:1523611
Chlopicki S et al. Obligatory role of lipid mediators in platelet-neutrophil adhesion. 2003 Thromb. Res. pmid:14592550
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Tencé M et al. Ether-phospholipid composition in neutrophils and platelets. 1985 Thromb. Res. pmid:4024039
Hadváry P and Baumgartner HR Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. 1983 Thromb. Res. pmid:6868019
Tan EL and Snyder F Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. 1985 Thromb. Res. pmid:4024051
Hayashi M et al. Detection of platelet-activating factor in exudates of rats with phorbol myristate acetate-induced pleurisy. 1987 Thromb. Res. pmid:3433255
Ding YA et al. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. 1995 Thromb. Res. pmid:7740521
Bussolino F et al. Intravascular release of platelet activating factor in children with sepsis. 1987 Thromb. Res. pmid:3441909
Suzuki K et al. The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. 1980 Feb 1-15 Thromb. Res. pmid:6966083
Ostermann G et al. Stimulation and desensitization of human and rabbit platelets by 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine and analogues. 1986 Thromb. Res. pmid:3764811
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Pfliegler G et al. Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. 1993 Thromb. Res. pmid:8503122
Altman R et al. Why single daily dose of aspirin may not prevent platelet aggregation. 1988 Thromb. Res. pmid:3140408
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Lecompte T et al. Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. 1990 Thromb. Res. pmid:2117306
McGowan EB and Detwiler TC Characterization of the thrombin-induced desensitization of platelet activation by thrombin. 1983 Thromb. Res. pmid:6356458
Kinlough-Rathbone RL et al. Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. 1999 Thromb. Res. pmid:10527409
May JA et al. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. 1997 Thromb. Res. pmid:9361371